NTM Facts

Skip to Content
For Patients NTMFacts
NTMFacts
  • Think
    WHAT IS NTM? Impact on NTM Patients Bronchiectasis and NTM Risk Who Else Is at Risk? NTM in Macrophages and Biofilm
  • Test
    Importance of early diagnosis How to Diagnose Collecting Sputum Microbiology Lab Interactions
  • Treat
    When to treat Airway clearance Initiating treatment Setting patient expectations Monitoring treatment response Adjusting treatment plan
  • A Thousand Words
    A Thousand Words Films A Thousand Words Art Gallery
  • NTM Articles
  • Resources
    For physicians For patients
  • Sign Up

Are you a healthcare professional?

If you are not, please click "No" and you will be redirected to our patient site, AboutNTM.com.

NO

You are about to leave NTMFacts.com

The site you are linking to is not controlled or endorsed by Insmed, and we are not responsible for the content.

Thank you for visiting NTMFacts.com.

OK
Click here to see NTM Guidelines from ATS, ERS, ESCMID, and IDSA Arrow
Think NTM

Think NTM

Raise your index of suspicion—bronchiectasis is a major risk factor for nontuberculous mycobacterial (NTM) lung disease. 63% (1158/1826) of bronchiectasis patients had coexistent NTM lung disease or NTM isolation in an analysis of the US Bronchiectasis Research Registry1,2

Test for NTM

Identify NTM sooner— it takes ~20 months from the first NTM-related symptom or diagnostic procedure for patients to receive an NTM diagnosis3,4

Test for NTM
Treat NTM

Treat NTM

The 2020 NTM Treatment Guidelines recommend treatment initiation rather than "watchful waiting" in diagnosed patients.* Retrospective studies have shown that most MAC patients who convert on treatment do so within 6 months after starting treatment5-8

*The decision should be individualized based on a combination of clinical factors.5

References reference arrow

References

  1. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis. 2013;17(11):e1000-e1004.
  2. Aksamit TR, O'Donnell AE, Barker A, et al; Bronchiectasis Research Registry Consortium. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151(5):982-992.
  3. Data on file. Insmed Incorporated. Bridgewater, NJ.
  4. Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc Respir Dis (Seoul). 2016;79(2):74-84.
  5. Daley CL, Iaccarino JM Jr, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa241.
  6. Furuuchi K, Morimoto K, Kurashima A, et al. Treatment duration and disease recurrence following the successful treatment of patients with Mycobacterium avium complex lung disease. Letter. Chest. 2020. doi:10.1016/j.chest.2019.12.016.
  7. Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Letter. Eur Respir J. 2019;53(5). doi:10.1183/13993003.01636-2018.
  8. Koh WJ, Moon SM, Kim SY, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50(3). doi:10.1183/13993003.02503-2016.
Insmed
  • Terms of Use
  • Privacy Policy
  • Sign Up
  • Accessibility Statement

This site is intended for healthcare professionals only. This site is for US audiences only.
© 2022 Insmed Incorporated. All Rights Reserved. Insmed is a trademark of Insmed Incorporated. NP-NTM-US-00028